ERBB2 and breast carcinoma: UALCAN database demonstrated that NONO expression levels of mRNA and protein were significantly upregulated across all the stages (stage 1–4) and subclasses (Luminal, HER2 positive, and TNBC) of breast cancer (Fig. 1f, g, supplementary Fig. S2A-C) These results showed that NONO expression and tumor progression are closely correlated and highlighting the potential of NONO as a promising target for the development of therapeutic strategies..